Skip Navigation

European Heart Journal 2000 21(5):354-364; doi:10.1053/euhj.1999.1717
Copyright © 2000 by the European Society of Cardiology.
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (22)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Cruickshank, J.M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cruickshank, J.M
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Review Article

Beta-blockers continue to surprise us

J.M Cruickshankf1

revised April 13, 1999; accepted April 14, 1999

Key Words: Beta-blockers, beta1selective beta-blockers, type II diabetes, hypertension, ACE inhibitors, captopril, atenolol, bisoprolol, UK Prospective Diabetes Study (UPDS)

f1 Correspondence: J. M. Cruickshank, DM, FRCP, 42 Harefield, Long Melford, Suffolk CO10 9DE, U.K.

References

  1. Lechat P, Packer M, Chalon S, Cusherat M, Arab T, Boissel J-P. Clinical effects of ß- adrenergic blockade in chronic heart failure. Circulation. 1998;98:1184–1191[Abstract/Free Full Text]
  2. Lancet. 1999;353:9–13[CrossRef][Web of Science][Medline]
  3. Lancet. 1999;353:2001–2007[CrossRef][Web of Science][Medline]
  4. BMJ. 1998;317:703–713[Abstract/Free Full Text]
  5. BMJ. 1998;317:713–720[Abstract/Free Full Text]
  6. Knight EL, Glynn RJ, McIntyre KM, Mogun H, Avorn J. Predictors of decreased renal function in patients with heart failure during ACE-inhibitor therapy; results for the SOLVD study. Am Heart J. 1999;138:849–855[CrossRef][Web of Science][Medline]
  7. Poldermans D, Boersma E, Bax JJ. The effect of bisoprolol on perioperative mortality and myocardial infarction in high risk patients undergoing vascular surgery. N Engl J Med. 1999;341:1789–1794[Abstract/Free Full Text]
  8. Cruickshank JM, Prichard BNC. Beta Blockers in Clinical Practice. Edinburgh, London, Madrid, Melbourne, New York, Tokyo: Churchill Livingstone; 1994. p. 949–57
  9. Eriksson JW, Jansen P-A, Foley K, Lithell H. Insulin sensitivity following treatment with the alpha, blocker bunazosin retard and the ß1-blocker atenolol in hypertensive non-insulin dependent diabetes mellitus patients. J Hypertens. 1996;14:1469–1475[CrossRef][Web of Science][Medline]
  10. Lancet. 1981;2:539–543[Medline]
  11. Cruickshank JM, Prichard BNC. Beta Blockers in Clinical Practice. Edinburgh, London, Madrid, Melbourne, New York, Tokyo: Churchill Livingstone; 1994. p. 975–6
  12. JAMA. 1982;247:1707–1714[Abstract/Free Full Text]
  13. Viskin S, Barron HV. Beta blockers prevent cardiac death following a myocardial infarction. Am J Cardiol. 1996;78:821–822[CrossRef][Web of Science][Medline]
  14. Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorthiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med. 1989;321:868–873[Abstract]
  15. Mathiesen ER, Hommel E, Giese J, Parving H-H. Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria. BMJ. 1991;303:81–87[Abstract/Free Full Text]
  16. Mogensen CE. Angiotension converting enzyme inhibitors and diabetic nephropathy. BMJ. 1992;304:327–328[Free Full Text]
  17. Hansson L, Zanchetti A, Carruthers SG. Effects of intensive blood pressure lowering and low dose aspirin in patients with hypertension; principle results of the HOT randomised trial. Lancet. 1998;351:1755–1762[CrossRef][Web of Science][Medline]
  18. Coope J, Warrender TS. Randomised trial of treatment of hypertension in elderly patients in primary care (HEP). BMJ. 1986;293:1145–1151[Abstract/Free Full Text]
  19. BMJ. 1992;304:405–412[Abstract/Free Full Text]
  20. JAMA. 1991;265:3255–3264[Abstract/Free Full Text]
  21. Podlowski S, Luther HP, Morwinski R, Müller J, Wallukat G. Agonistic anti ß1receptor autoantibodies from cardiomyopathic patients reduce the ß1adrenergic receptor expression in neonatal rat cardiomyocytes. Circulation. 1998;98:2470–2476[Abstract/Free Full Text]
  22. Luchner A, Burnett JC, Jougasaki M, Hense H-W, Riegger GAJ, Schunkert H. Augmentation of the cardiac naturetic peptides by beta-receptor antagonism. J Am Coll Cardiol. 1998;32:1839–1844[Abstract/Free Full Text]
  23. Krum H, Gu A, Wiltshire-Clement M. Changes in plasma endothelin-1 levels reflects clinical response to B-blockade in chronic heart failure. Am Heart J. 1996;131:337–341[CrossRef][Web of Science][Medline]
  24. Cockcroft JR, Chowienczyk PJ, Brett SE. Nebivolol vasodilates human forearm vasculature; evidence for a L-arginine/No-dependent mechanism. J Pharm Exp Ther. 1995;274:1067–1071[Abstract/Free Full Text]
  25. Cruickshank JM, Degaute JP, Kuurne T. Reduction of stress/catecholamine induced cardiac necrosis by ß1selective blockade. Lancet. 1987;2:585–589[CrossRef][Web of Science][Medline]
  26. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction; an overview of the randomised trials. Prog Cardiovasc Dis. 1985;xxvii (5):335–371
  27. J Am Coll Cardiol. 1996;28:20–24[Abstract]
  28. Kennedy HL. Beta blocker prevention of pro-arrhythmia and pro-ischaemia; Clues from CAST, CAMIAT & EMIAT. Am J Cardiol. 1997;80:1208–1211[CrossRef][Web of Science][Medline]
  29. J Hypertens. 1985;3:379–392[Web of Science][Medline]
  30. BMJ. 1985;291:97–104[Abstract/Free Full Text]
  31. Preston RA, Materson BJ, Reda DJ. Age-race subgroup compared with renin profile as predictors of blood pressure response to antihypertensive therapy. JAMA. 1998;280:1168–1172[Abstract/Free Full Text]
  32. Wikstrand J. Beta blockers and cardioprotection—is there any good news from the recent trials. J Clin Pharm Ther. 1987;12:347–350[Web of Science][Medline]
  33. Miall WE, Greeberg G. Mild hypertension; is there pressure to treat?. Cambridge: Cambridge University Press; 1987. p. 78–94
  34. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta blockade on mortality among high risk and low risk patients after myocardial infarction. N Engl J Med. 1998;339:489–497[Abstract/Free Full Text]
  35. Lund-Johansen P. Central haemodynamics in essential hypertension at rest and during exercise; a 20 year follow up study. J Hypertens. 1989;7:52–55
  36. Gordon T, Moor FE, Shurtleff D, Dawber TR. Some methodologic problems in long term study of cardiovascular disease; observations on the Framingham Study. J Chron Dis. 1959;:186–206
  37. Strauer BE. Development of cardiac failure by coronary small vessel disease in hypertensive heart disease. J Hypertens. 1991;9:S11–S21
  38. Cruickshank JM, Prichard BNC. Beta-blockers in Clinical Practice. Edinburgh, London, Madrid, Melbourne, New York, Tokyo: Churchill Livingstone; 1994. p. 157–8
  39. Bart BA. Concern for azotemia with ACE inhibitors: public health implications and clinical relevance. Am Heart J. 1999;138:801–803[CrossRef][Web of Science][Medline]
  40. Cruickshank JM, Prichard BNC. Beta Blockers in Clinical Practice. Edinburgh, London, Madrid, Melbourne, New York, Tokyo: Churchill Livingstone; 1994. p. 203
  41. Cruickshank JM, Prichard BNC. Beta Blockers in Clinical Practice. Edinburgh, London, Madrid, Melbourne, New York, Tokyo: Churchill Livingstone; 1994. p. 976–8
  42. Julian DG, Jackson FS, Prescott RJ, Szekely P. Controlled trial of Sotalol for 1 year after myocardial infarction. Lancet. 1982;1:1142–1147[CrossRef][Web of Science][Medline]
  43. Waldo AL, Camm AJ, de Ruyter H. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet. 1996;348:7–12[CrossRef][Web of Science][Medline]
  44. Packer M, Bristow MR, Cohn JN. The effect of carvedilol on mortality in patients with chronic heart failure. N Engl J Med. 1996;334:1349–1355[Abstract/Free Full Text]
  45. Communal C, Singh K, Sawyer DB, Colucci WS. Opposing effects of beta1 and beta2 adrenergic receptors on cardiac myocyte apoptosis. Circulation. 1999;100:2210–2212[Abstract/Free Full Text]
  46. Man in't Veld AJ, Schalekamp ADH. Effects of ten different beta blockers on haemodynamics, plasma renin activity and plasma norepinephrine in hypertension; the key role of vascular resistance changes in relation to partial agonist activity. J Cardiovasc Pharmocol. 1983;5:S30–45
  47. Cruickshank JM, Prichard BNC. Beta Blockers in Clinical Practice. Edinburgh, London, Madrid, Melbourne, New York, Tokyo: Churchill Livingstone; 1994. p. 391–6
  48. Wellstein A. Affinity and selectivity of beta receptor antagonists in vitro. J Cardiovasc Pharmocol. 1986;8:S36–40
  49. Neutel JM, Smith DHG, Ram CVS. Application of ambulatory blood pressure monitoring in differentiating between antihypertensive agents. Am J Med. 1993;94:181–187[CrossRef][Web of Science][Medline]
  50. Cruickshank, JM, Prichard, BNC, Beta blockers in Clinical Practice, Edinburgh, London, Madrid, Melbourne, New York, Tokyo, Churchill Livingstone, 1994, 127, 33
  51. Dorrow P. Effects of single oral doses of bisoprolol and atenolol on airways function in non-asthmatic chronic obstructive lung disease and angina pectoris. Eur J Clin Pharmacol. 1986;31:143[CrossRef][Web of Science][Medline]
  52. Eriksson JW, Jansson PA, Foley K, Lithell H. Insulin sensitivity following treatment with the alpha blocker bunazasin retard and the beta blocker atenolol in hypertensive non-insulin dependent diabetes mellities patients. J Hypertens. 1996;14:1469–1475[CrossRef][Web of Science][Medline]
  53. Heinemann L, Heise T, Ampudia J. Four week administration of an ACE inhibitor and a cardioselective Beta blocker in healthy volunteers; no influence on insulin sensitivity. Eur J Clin Invest. 1995;25:595–600[Web of Science][Medline]
  54. Cruickshank JM, Prichard BNC. Beta blockers in Clinical Practice. Edinburgh, London, Madrid, Melbourne, New York, Tokyo: Churchill Livingstone; 1994. p. 950–-7
  55. Lauridsen UB, Chistensen NJ, Lyngsoe J. Effects of non-selective and beta1selective blockade on glucose metabolism and hormone responses during insulin induced hypoglycaemia in normal man. J Clin Endocrin Metab. 1983;56:876–882[Abstract/Free Full Text]
  56. Ryan JR, La Corte W, Jain A, McMahon FG. Hypertension in hypoglycaemic diabetics treated with beta blockers. Hypertension. 1985;7:443–446[Abstract/Free Full Text]
  57. Smith U, Lager I. Beta blockade in diabetics. N Engl J Med. 1978;299:1467[Medline]
  58. Kennedy TL, Stanley C, Baker L, Norman ME. Malignant hypertension associated with propranolol-induced hypoglycaemia. Kidney Int. 1979;16:906
  59. Maltbaek N, Rehling M, Tango M, Trap-Jensen J, Lysbo-Svendsen T. Adrenergic beta receptor blockade; haemodynamic relevance of beta1-selectivity and ISA during adrenaline infusion. Acta Med Scand Suppl. 1983;677:21–25[Medline]
  60. Trap-Jensen J, Carlsen JE, Lysbo-Svendsen T, Christiansen NJ. Cardiovascular and adrenergic effects of cigarette smoking during immediate non-selective and selective beta blockade in humans. Eur J Clin Invest. 1979;9:181–183[Web of Science][Medline]
  61. Wikstrand J, Warnold I, Olsson G, Tuomilehto J, Elmfeldt D, Berglund G. Primary prevention with metoprolol in patients with hypertension: mortality results from MAPHY study. JAMA. 1988;259:1976–1982[Abstract/Free Full Text]
  62. Fox K, Jonathan A, Williams H, Selwyn A. Interaction between cigarettes and propranolol in treatment of angina pectoris. BMJ. 1980;281:191–193[Abstract/Free Full Text]
  63. Day JL, Metcalf J, Simpson CN. Adrenergic mechanisms in control of plasma lipid concentrations. BMJ. 1982;284:1145–1148[Abstract/Free Full Text]
  64. Frithz G, Weiner L. Effects of bisoprolol dosed once daily, on blood pressure and serum lipids and HDL cholesterol in patients with mild to moderate hypertension. Eur J Clin Pharmacol. 1987;32:77[CrossRef][Web of Science][Medline]
  65. Cruickshank JM, Prichard BNC. Beta Blockers in Clinical Practice. Edinburgh, London, Madrid, Melbourne, New York, Tokyo: Churchill Livingstone; 1994. p. 918–28
  66. Clausen T, Flatman JA. Beta2-adrenoceptors mediate the stimulating effect of adrenaline on active electrogenic Na-K transport in rat soleus muscle. Br J Pharmacol. 1980;68:749–755[Web of Science][Medline]
  67. Kaiser P. Physical performance ad muscle metabolism during beta adrenergic blockade in man. Acta Physiol Scand Suppl. 1984;536:1–53[Medline]
  68. Cleroux J, Van Nguyen P, Taylor AW, Leenhan FHH. Long duration exercise with beta blockade; endurance versus skeletal muscle fibre composition. J Hypertens. 1987;5:S197–199
  69. Croog SH, Levine S, Testa MA. The effects of antihypertensive therapy on the quality of life. N Engl J Med. 1986;314:1657–1664[Abstract]
  70. Steiner SS, Friedhoff AJ, Wilson BL, Wecker JR, Santo J-AP. Antihypertensive therapy and quality of life; a comparison of atenolol, captopril, enalapril and propranolol. J Hum Hypertens. 1990;4:217–225[Web of Science][Medline]
  71. Fletcher AE, Bulpitt CJ, Hawkins CM. Quality of life on antihypertensive therapy; a randomised double blind controlled trial of captopril and atenolol. J. Hypertens. 1990;8:463–466[CrossRef][Web of Science][Medline]
  72. Prichard BNC, Saul PA. Comparison of beta blockade and ACE inhibition in the treatment of hypertension. J Cardiovasc Pharmcol. 1989;16:81–85
  73. Philipp T, Anlauf M, Distler A, Holtzreve H, Michaelis J, Wellek S. Randomised, double-blind, multicentre comparison of hydro-chorthiazide, atenolol, nitrendepine and enalapril in antihypertensive treatment; results of the HANE Study. BMJ. 1997;315:154–159[Abstract/Free Full Text]
  74. Preston RA, Materson BJ, Reda DJ. Age-race, subgroup compared with renin profile as predictors of blood pressure response to antihypertensive therapy. JAMA. 1998;280:1168–1172[Abstract/Free Full Text]
  75. Messerli FH, Grossman E, Goldbourt U. Are B-blockers efficacious as first-line therapy for hypertension in the elderly. JAMA. 1998;279:1903–1907[Abstract/Free Full Text]
  76. Lever AF, Ramsey LE. Treatment of hypertension in the elderly. J Hypertens. 1995;13:571–579[CrossRef][Web of Science][Medline]
  77. Curb JD, Pressel SL, Cutler JA. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA. 1996;276:1886–1892[Abstract/Free Full Text]
  78. Staessen JA, Fagard R, Thijs L. Randomised double blend comparison of placebo and active treatment for old patients with isolated systolic hypertension. Lancet. 1997;350:757–764[CrossRef][Web of Science][Medline]
  79. Tuomilehto J, Rastenyte D, Birkenhager WH. Effect of calcium channel blockade in older patients with diabetes and systolic hypertension. N Eng J Med. 1999;340:677–684[Abstract/Free Full Text]
  80. Hansson L, Lindholm LH, Ekbom T. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity—the Swedish Trial in Old Patients with Hypertension—2 Study. Lancet. 1999;354:1751–1756[CrossRef][Web of Science][Medline]
  81. Wikstrand J, Warnold I, Olsson G, Tuomilehto J, Elmfeldt D, Berglund G. Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY Study. JAMA. 1986;259:1976–1982
  82. Hansson L, Lindholm LH, Niskanen L. Effect of angiotension-converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension; the Captropril Prevention Project (CAPP) randomised trial. Lancet. 1999;353:611–616[CrossRef][Web of Science][Medline]
  83. McMahon S, Peto R, Curler J. Blood pressure, stroke and coronary artery disease. Part 1—Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335:765–774[CrossRef][Web of Science][Medline]
  84. Beevers DG. Beta blockers for hypertension; time to call a halt. J Hum Hypertens. 1998;12:807–810[CrossRef][Web of Science][Medline]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 HypertensionHome page
D. C. Kem, X. Yu, E. Patterson, S. Huang, S. Stavrakis, B. Szabo, L. Olansky, J. McCauley, and M. W. Cunningham
Autoimmune Hypertensive Syndrome
Hypertension, November 1, 2007; 50(5): 829 - 834.
[Full Text] [PDF]

Home page
 Anesth. Analg.Home page
O. Schouten, J. J. Bax, M. Dunkelgrun, H. H.H. Feringa, and D. Poldermans
Pro: Beta-Blockers Are Indicated for Patients at Risk for Cardiac Complications Undergoing Noncardiac Surgery
Anesth. Analg., January 1, 2007; 104(1): 8 - 10.
[Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
K. A. Eagle and W. C. Lau
Any Need for Preoperative Cardiac Testing in Intermediate-Risk Patients With Tight Beta-Adrenergic Blockade?
J. Am. Coll. Cardiol., September 5, 2006; 48(5): 970 - 972.
[Full Text] [PDF]

Home page
 CirculationHome page
H. H.H. Feringa, J. J. Bax, E. Boersma, M. D. Kertai, S. H. Meij, W. Galal, O. Schouten, I. R. Thomson, P. Klootwijk, M. R.H.M. van Sambeek, et al.
High-Dose {beta}-Blockers and Tight Heart Rate Control Reduce Myocardial Ischemia and Troponin T Release in Vascular Surgery Patients
Circulation, July 4, 2006; 114(1_suppl): I-344 - I-349.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
D. Poldermans and E. Boersma
Beta-Blocker Therapy in Noncardiac Surgery
N. Engl. J. Med., July 28, 2005; 353(4): 412 - 414.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
B.N.C. Prichard and J.M. Robin
Beta-blockade and surgery
Eur. Heart J., August 1, 2001; 22(15): 1253 - 1255.
[Abstract] [PDF]

Home page
 Eur Heart JHome page
D Poldermans, E Boersma, J.J Bax, I.R Thomson, B Paelinck, L.L.M van de Ven, M.G Scheffer, G Trocino, C Vigna, H.F Baars, et al.
Bisoprolol reduces cardiac death and myocardial infarction in high-risk patients as long as 2 years after successful major vascular surgery
Eur. Heart J., August 1, 2001; 22(15): 1353 - 1358.
[Abstract] [PDF]

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (22)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Cruickshank, J.M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cruickshank, J.M
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?